The standard-risk (survival 75–90%) population includes non-metastatic SHH patients excluding TP53-mutated or MYCN amplified tumors, non-metastatic Group 3 MBs with no MYC amplification, and non-metastatic Group 4 MBs without chromosome 11 loss [11, 51, 65]. Here, MYCN is linked to Mobius syndrome.